CD274（程序性死亡配体1，PD-L1）/PDCD1（程序性死亡受体1，PD-1）在初发和转化型弥漫性大B细胞淋巴瘤中的表达 - Suppr

Suppr

超能文献

CD274 (PD-L1)/PDCD1 (PD-1) expression in de novo and transformed diffuse large B-cell lymphoma.

作者信息

Kwiecinska Anna, Tsesmetzis Nikolaos, Ghaderi Mehran, Kis Lorand, Saft Leonie, Rassidakis George Z

机构信息

Department of Pathology and Cytology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.

出版信息

Br J Haematol. 2018 Mar;180(5):744-748. doi: 10.1111/bjh.14432. Epub 2016 Nov 23.

DOI:10.1111/bjh.14432

PMID:27879989

Abstract

摘要

相似文献

CD274 (PD-L1)/PDCD1 (PD-1) expression in de novo and transformed diffuse large B-cell lymphoma.CD274（程序性死亡配体1，PD-L1）/PDCD1（程序性死亡受体1，PD-1）在初发和转化型弥漫性大B细胞淋巴瘤中的表达

Br J Haematol. 2018 Mar;180(5):744-748. doi: 10.1111/bjh.14432. Epub 2016 Nov 23.

Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.弥漫性大 B 细胞淋巴瘤肿瘤微环境中程序性细胞死亡蛋白 1 和程序性细胞死亡配体 1 表达的临床病理分析。

Histopathology. 2016 Jun;68(7):1079-89. doi: 10.1111/his.12882. Epub 2015 Dec 1.

Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.程序性细胞死亡蛋白1/程序性细胞死亡配体1在原发性胃肠道弥漫性大B细胞淋巴瘤肿瘤微环境中的表达

Pathol Res Pract. 2018 Apr;214(4):507-512. doi: 10.1016/j.prp.2018.03.001. Epub 2018 Mar 12.

Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.程序性细胞死亡配体1（PD-L1）在弥漫性大B细胞淋巴瘤中的表达及临床价值：一项回顾性研究

Chin J Cancer. 2017 Dec 16;36(1):94. doi: 10.1186/s40880-017-0262-z.

PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.PD-L1 和 PD-L2 在原发性皮肤弥漫性大 B 细胞淋巴瘤，腿型中由巨噬细胞或肿瘤细胞差异表达。

Am J Surg Pathol. 2018 Mar;42(3):326-334. doi: 10.1097/PAS.0000000000000983.

PD-1 is highly expressed by neoplastic B-cells in Richter transformation.在Richter转化中，肿瘤性B细胞高表达程序性死亡受体1（PD-1）。

Br J Haematol. 2019 Apr;185(2):370-373. doi: 10.1111/bjh.15514. Epub 2018 Jul 20.

PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.EBV 阴性弥漫性大 B 细胞淋巴瘤中 PD-L1 的表达：临床病理特征及预后意义

Oncotarget. 2016 Sep 13;7(37):59976-59986. doi: 10.18632/oncotarget.11045.

Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets.原发性皮肤弥漫性大B细胞淋巴瘤中的肿瘤微环境与检查点分子——新的治疗靶点

Am J Surg Pathol. 2017 Jul;41(7):998-1004. doi: 10.1097/PAS.0000000000000851.

The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now.抗程序性死亡蛋白1（PD-1）和抗程序性死亡配体1（PD-L1）药物在弥漫性大B细胞淋巴瘤治疗中的作用：未来已来。

Crit Rev Oncol Hematol. 2017 May;113:52-62. doi: 10.1016/j.critrevonc.2017.02.027. Epub 2017 Mar 9.

Clinicopathological analysis of immunohistochemical expression of immune checkpoint molecules in follicular lymphoma.滤泡性淋巴瘤免疫检查点分子免疫组化表达的临床病理分析。

Hematol Oncol. 2022 Oct;40(4):530-540. doi: 10.1002/hon.2972. Epub 2022 Feb 11.

引用本文的文献

Tumor-Associated Macrophages as Key Modulators of Disease Progression in Diffuse Large B-Cell Lymphoma.肿瘤相关巨噬细胞作为弥漫性大B细胞淋巴瘤疾病进展的关键调节因子

Biomedicines. 2025 May 1;13(5):1099. doi: 10.3390/biomedicines13051099.

Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art.程序性死亡配体 1（PD-L1）在淋巴瘤中的表达：最新进展。

Int J Mol Sci. 2024 Jun 11;25(12):6447. doi: 10.3390/ijms25126447.

Diffuse Large B Cell Lymphoma Arising in Patients with Preexisting Hodgkin Lymphoma.原有 Hodgkin 淋巴瘤患者中发生的弥漫性大 B 细胞淋巴瘤。

Curr Oncol. 2022 Aug 25;29(9):6115-6124. doi: 10.3390/curroncol29090480.

The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas.正常生发中心和弥漫性大B细胞淋巴瘤中的PD-1/PD-L1检查点

Cancers (Basel). 2021 Sep 18;13(18):4683. doi: 10.3390/cancers13184683.

Development and Validation of a Novel Risk Stratification Model for Cancer-Specific Survival in Diffuse Large B-Cell Lymphoma.弥漫性大B细胞淋巴瘤癌症特异性生存新型风险分层模型的开发与验证

Front Oncol. 2021 Jan 14;10:582567. doi: 10.3389/fonc.2020.582567. eCollection 2020.

Immune-Checkpoint Inhibitors in B-Cell Lymphoma.B细胞淋巴瘤中的免疫检查点抑制剂

Cancers (Basel). 2021 Jan 8;13(2):214. doi: 10.3390/cancers13020214.

Using Machine Learning Modeling to Explore New Immune-Related Prognostic Markers in Non-Small Cell Lung Cancer.使用机器学习建模探索非小细胞肺癌新的免疫相关预后标志物。

Front Oncol. 2020 Oct 30;10:550002. doi: 10.3389/fonc.2020.550002. eCollection 2020.

Synergistic effect of programmed death-1 inhibitor and programmed death-1 ligand-1 inhibitor combined with chemotherapeutic drugs on DLBCL cell lines and .程序性死亡蛋白1抑制剂和程序性死亡蛋白1配体1抑制剂与化疗药物联合应用对弥漫性大B细胞淋巴瘤细胞系的协同作用及……（原文此处不完整）

Am J Cancer Res. 2020 Sep 1;10(9):2800-2812. eCollection 2020.

Advances in targeted therapy for malignant lymphoma.恶性淋巴瘤靶向治疗的进展。

Signal Transduct Target Ther. 2020 Mar 6;5(1):15. doi: 10.1038/s41392-020-0113-2.

[Study on enhancing the killing activity of chemotherapy drugs by PD-1 inhibitor on Raji cell line].[PD-1抑制剂增强化疗药物对Raji细胞系杀伤活性的研究]

Zhonghua Xue Ye Xue Za Zhi. 2020 Jan 14;41(1):76-79. doi: 10.3760/cma.j.issn.0253-2727.2020.01.015.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验